Corvus Pharmaceuticals CRVS
NASDAQ CRVS
$11.76 -0.11 (-0.93%)
At close: Sep 29, 2026 · 4:00 PM EDT

Corvus Pharmaceuticals (CRVS) Common Equity (2015 - 2026)

Updated

Corvus Pharmaceuticals' Common Equity came in at $225.33 million for Q2 2026, up 180.9% from $80.23 million a year earlier but down 6.4% from the prior quarter.

Analysis

Corvus Pharmaceuticals (CRVS) Common Equity (2015 - 2026) Analysis & Trends

At the end of FY2025, Corvus Pharmaceuticals' Common Equity was $61.21 million, up 87.9% from FY2024.

  • Common Equity carries a five-year compound annual growth rate of -3.2% (FY2020 to FY2025).
  • Going back by year, Common Equity was $32.57 million in FY2024 (-15.8%), $38.68 million in FY2023 (-31.1%), $56.12 million in FY2022 (-42.2%) and $97.16 million in FY2021 (+34.7%).
  • The five-year range for quarterly Common Equity is $12.41 million (Q3 2024) to $240.68 million (Q1 2026).
  • Year-over-year, Common Equity has increased for six consecutive quarters, with growth averaging 144.0% over the last eight quarters.
  • The fastest year-over-year change in Common Equity over five years came in Q3 2025 (growth of 478.4%), and the weakest in Q3 2024 (a decline of 72.0%).
  • Business Quant data shows CRVS's Common Equity at $240.68 million (Q1 2026), $61.21 million (Q4 2025) and $71.77 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 84.97 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn -5.94 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 41.98 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 41.95 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 50.37 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 11.69 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 11.83 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 85.49 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 20.25 Bn
10 Corvus Pharmaceuticals 998.52 Mn 486.96 Mn - 225.33 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 225.33 Mn
Mar 31, 2026 240.68 Mn
Dec 31, 2025 61.21 Mn
Sep 30, 2025 71.77 Mn
Jun 30, 2025 80.23 Mn
Mar 31, 2025 49.33 Mn
Dec 31, 2024 32.57 Mn
Sep 30, 2024 12.41 Mn
Jun 30, 2024 51.23 Mn
Mar 31, 2024 33.36 Mn
Dec 31, 2023 38.68 Mn
Sep 30, 2023 44.29 Mn
Jun 30, 2023 49.48 Mn
Mar 31, 2023 48.87 Mn
Dec 31, 2022 56.12 Mn
Sep 30, 2022 64.68 Mn
Jun 30, 2022 80.39 Mn
Mar 31, 2022 89.72 Mn
Dec 31, 2021 97.16 Mn
Sep 30, 2021 105.15 Mn
API Access

Corvus Pharmaceuticals Common Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=common-equity&ticker=CRVS&period=max&api_key=YOUR_API_KEY